The Head of Government of Mexico City, Claudia Sheinbaum, and the authorities of the Ministry of Health reported that in the capital a second treatment protocol is applied against COVID-19 with a medicine called favipiravirBut what does it consist of and how does it work? Here we tell you:
What is favipiravir?
An article published in Elsevier points out that the favipiravir is a drug that has a mechanism similar to remdesivir (antiviral medicine) but administered orally. In Japan it is known under its trade name Avigan and serves as a treatment for influenza.
How does this treatment work?
Favipiravir prevents viruses from copying their genetic material through a mechanism of action to selectively inhibit the RNA polymerase involved in the reproduction of the influenza virus.
“High concentrations of favipiravir were found to be needed to inhibit SARS-CoV-2 infection in Vero cells.. Therefore, it is difficult to determine the basis on which the current dose of this drug has been established in the virus that causes COVID-19 ″
Article of Elsevier
This of the high concentrations of favipiravir coincides with that indicated in a study published in recent days in the Proceedings of the National Academy of Sciences of the United States of America (PNAS).
The study authors assure that the lack of consensus on the use of hydroxychloroquine for COVID-19 patients led them to evaluate the efficacy of drugs against SARS-CoV-2.
“This urgent need for effective treatment coupled with the lack of small animal models of infection has led to clinical trials using repurposed drugs without preclinical evidence of their efficacy“
This was pointed out by specialists who used small animals infected with SARS-CoV-2 to test favipiravir.
Does Favipiravir Really Work?
The same study reports:
“High doses of favipiravir significantly reduced infectious virus titers in the lungs and markedly improved lung histopathology. In addition, a high dose of favipiravir decreased the transmission of the virus by direct contact, while hydroxychloroquine failed as prophylaxis ”
He CDMX government He started the treatment two months ago and will test it on approximately 280 people and will take six months of evaluation.